Chronic Periodontitis - Pipeline Insight, 2024

Chronic Periodontitis - Pipeline Insight, 2024

DelveInsight’s, “Chronic Periodontitis - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chronic Periodontitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Chronic Periodontitis: Understanding

Chronic Periodontitis: Overview

Periodontal disease and dental caries are the most common diseases in the oral cavity. Chronic periodontitis is one of the periodontal diseases. It is a long-lasting inflammatory disease affecting the soft and hard tissues around the teeth and it is common worldwide. This disease is related to common and preventable biological risk factors (e.g., high blood pressure, high blood cholesterol, diabetes, genetic factors, and obesity) and behavioral risk factors (e.g., an unhealthy diet, physical inactivity, and tobacco use). Chronic periodontitis is ideally diagnosed at the beginning of the disease.

""Chronic Periodontitis- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Periodontitis pipeline landscape is provided which includes the disease overview and Chronic Periodontitis treatment guidelines. The assessment part of the report embraces, in depth Chronic Periodontitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence in Chronic Periodontitis R&D. The therapies under development are focused on novel approaches to treat/improve in Chronic Periodontitis.

This segment of the Chronic Periodontitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Periodontitis Emerging Drugs

• ST 266: Noveome

ST266 is a cell-free biologic made by culturing a novel population of human amnion-derived cells. Through a proprietary culturing method, these cells produce an array of growth factors and cytokines, known as the secretome, which promote cellular survival and reduce inflammation.

Further product details are provided in the report……..

Chronic Periodontitis: Therapeutic Assessment

This segment of the report provides insights about the different Chronic Periodontitis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Chronic Periodontitis

There are approx. 10+ key companies which are developing the therapies for Chronic Periodontitis. The companies which have their Chronic Periodontitis drug candidates in the most advanced stage, i.e. Phase II include, Noveome

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Chronic Periodontitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Molecule Type

Products have been categorized under various Molecule types such as

• Peptide
• Protein
• Propylene glycols
• Cell Therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Periodontitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Periodontitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Periodontitis drugs.

Chronic Periodontitis Report Insights

• Chronic Periodontitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chronic Periodontitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Chronic Periodontitis drugs?
• How many Chronic Periodontitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Periodontitis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Periodontitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chronic Periodontitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Amyndas Pharmaceuticals
• Takeda
• CSL behring
• Vaxcyte
• Noveome
• Perioc

Key Products

• AMY 101
• GXV 003
• Research programme: periodontitis vaccines
• VAX PG
• ST 266
• Ciclosporin topical gel